Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability.

Slupianek A, Falinski R, Znojek P, Stoklosa T, Flis S, Doneddu V, Pytel D, Synowiec E, Blasiak J, Bellacosa A, Skorski T.

Leukemia. 2013 Mar;27(3):629-34. doi: 10.1038/leu.2012.294. Epub 2012 Oct 9.

3.

Reactive oxygen species in BCR-ABL1-expressing cells - relevance to chronic myeloid leukemia.

Antoszewska-Smith J, Pawlowska E, Blasiak J.

Acta Biochim Pol. 2017;64(1):1-10. doi: 10.18388/abp.2016_1396. Epub 2016 Dec 1. Review.

4.

Molecular biology of bcr-abl1-positive chronic myeloid leukemia.

Quintás-Cardama A, Cortes J.

Blood. 2009 Feb 19;113(8):1619-30. doi: 10.1182/blood-2008-03-144790. Epub 2008 Sep 30. Review.

5.

DNA Repair--A Double-Edged Sword in the Genomic Stability of Cancer Cells--The Case of Chronic Myeloid Leukemia.

Pawlowska E, Blasiak J.

Int J Mol Sci. 2015 Nov 18;16(11):27535-49. doi: 10.3390/ijms161126049. Review.

6.

Genetic mechanisms of chronic myeloid leukemia blastic transformation.

Skorski T.

Curr Hematol Malig Rep. 2012 Jun;7(2):87-93. doi: 10.1007/s11899-012-0114-5. Review.

PMID:
22328017
7.

Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression.

Ernst T, Hochhaus A.

Semin Oncol. 2012 Feb;39(1):58-66. doi: 10.1053/j.seminoncol.2011.11.002. Review.

PMID:
22289492
8.

Diagnosing and managing advanced chronic myeloid leukemia.

Deininger MW.

Am Soc Clin Oncol Educ Book. 2015:e381-8. doi: 10.14694/EdBook_AM.2015.35.e381. Review.

9.

Characterization of cancer stem cells in chronic myeloid leukaemia.

Jørgensen HG, Holyoake TL.

Biochem Soc Trans. 2007 Nov;35(Pt 5):1347-51. Review.

PMID:
17956348
10.

Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.

Baccarani M, Soverini S, De Benedittis C.

Am Soc Clin Oncol Educ Book. 2014:167-75. doi: 10.14694/EdBook_AM.2014.34.167. Review.

11.

Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia - is it all BCR-ABL?

Rumpold H, Webersinke G.

Curr Cancer Drug Targets. 2011 Jan;11(1):3-19. Review.

PMID:
21062244
12.

BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.

Burke BA, Carroll M.

Leukemia. 2010 Jun;24(6):1105-12. doi: 10.1038/leu.2010.67. Epub 2010 May 6. Review.

13.

Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.

Soverini S, de Benedittis C, Mancini M, Martinelli G.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S120-8. doi: 10.1016/j.clml.2015.02.035. Review.

PMID:
26297264
14.

Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.

Eide CA, O'Hare T.

Curr Hematol Malig Rep. 2015 Jun;10(2):158-66. doi: 10.1007/s11899-015-0248-3. Review.

15.

Molecular and cellular bases of chronic myeloid leukemia.

Chen Y, Peng C, Li D, Li S.

Protein Cell. 2010 Feb;1(2):124-32. doi: 10.1007/s13238-010-0016-z. Epub 2010 Feb 6. Review.

16.

Molecular monitoring of chronic myeloid leukemia: present and future.

Yeung CC, Egan D, Radich JP.

Expert Rev Mol Diagn. 2016 Oct;16(10):1083-1091. Epub 2016 Sep 6. Review.

17.

The chronic myeloid leukemia stem cell: stemming the tide of persistence.

Holyoake TL, Vetrie D.

Blood. 2017 Mar 23;129(12):1595-1606. doi: 10.1182/blood-2016-09-696013. Epub 2017 Feb 3. Review.

PMID:
28159740
18.

New Methodologies in the Molecular Monitoring of CML.

Yeung CC, Egan D, Radich J.

Curr Hematol Malig Rep. 2016 Apr;11(2):94-101. doi: 10.1007/s11899-016-0303-8. Review.

PMID:
26946301
19.

BCR/ABL1 fusion transcripts generated from alternative splicing: implications for future targeted therapies in Ph+ leukaemias.

Chiarella P, Summa V, De Santis S, Signori E, Picardi E, Pesole G, Saglio G, Fazio VM.

Curr Mol Med. 2012 Jun;12(5):547-65. Review.

PMID:
22300134
20.

Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach.

Keramatinia A, Ahadi A, Akbari ME, Mohseny M, Jarahi AM, Mehrvar N, Mansouri N, Tabatabaei SAM, Movafagh A.

J Cancer Prev. 2017 Jun;22(2):74-81. doi: 10.15430/JCP.2017.22.2.74. Epub 2017 Jun 30. Review.

Supplemental Content

Support Center